Keywords: CBT; cognitive behavioral therapy; CYP2D6; cytochrome P450 2D6; DHEA; dehydroepiandrosterone; FDA; Food and Drug Administration; GSM; genitourinary syndrome of menopause; MPA; medroxyprogesterone acetate; SERM; selective estrogen receptor modulator; SGB;